FDAnews
www.fdanews.com/articles/193522-glenmarks-abiraterone-acetate-tablets-approved
Grey Approved Stamp

Glenmark’s Abiraterone Acetate Tablets Approved

November 20, 2019

The FDA approved Glenmark Pharmaceuticals’ abiraterone acetate 250 mg as a generic of Janssen’s prostate cancer drug Zytiga (abiraterone).

Janssen earned approximately $794 million from sales of the Zytiga 250 mg for the 12-month period ending August 2019.

The approval brings Glenmark’s portfolio to 162 products authorized for distribution in the U.S., with 46 ANDA’s pending approval, the company said.

View today's stories